AOD-9604 does not influence the WADA hGH isoform immunoassay

Drug Testing and Analysis

Volumn 5, Issue 11-12, 2013, Pages 850-852

  Orlovius, A K ^a   Thomas, A ^a   Schanzer W ^a   Thevis, M ^a,b  

^a GERMAN SPORT UNIVERSITY COLOGNE   (Germany)

^b European Monitoring Center for Emerging Doping Agents   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

ISOFORMS;

HUMAN GROWTH HORMONE[176-191][176 TYROSINE];

CHEMOLUMINESCENCE; DOPING; HUMAN; IMMUNOASSAY; LETTER; LIPOGENESIS; LIPOLYSIS; LIQUID CHROMATOGRAPHY; LYOPHILISATE; PRIORITY JOURNAL; TANDEM MASS SPECTROMETRY;

FEMALE; HUMAN GROWTH HORMONE; HUMANS; IMMUNOASSAY; MALE; MASS SPECTROMETRY; PEPTIDE FRAGMENTS; PROTEIN ISOFORMS; SENSITIVITY AND SPECIFICITY; SOMATOSTATIN;

EID: 84890793192     PISSN: 19427603     EISSN: 19427611     Source Type: Journal    
DOI: 10.1002/dta.1557     Document Type: Letter

References (11)

1. F.M. Ng, J. Sun, L. Sharma, R. Libinaka, W.J. Jiang, R. Gianello Metabolic studies of a synthetic lipolytic domain (AOD9604) of human growth hormone. Horm. Res. 2000, 53, 274.
2. M. Heffernan, R.J. Summers, A. Thorburn, E. Ogru, R. Gianello, W.J. Jiang, F.M. Ng The effects of human GH and its lipolytic fragment (AOD9604) on lipid metabolism following chronic treatment in obese mice and beta(3)-AR knock-out mice. Endocrinology 2001, 142, 5182.
3. WADA statement on substance AOD-9604. Available at: http://playtrue.wada-ama.org/news/wada-statement-on-substance-aod-9604/?utm_source=rss&utm_medium=rss&utm_campaign=wada-statement-on-substance-aod-9604 [3 May 2013].
4. WADA. The 2013 Prohibited List. Available at: www.wada-ama.org/Documents/World_Anti-Doping_Program/WADP-Prohibited-list/2013/WADA-Prohibited-List-2013-EN.pdf [14 May 2013].
5. M. Bidlingmaier, J. Suhr, A. Ernst, Z. Wu, A. Keller, C.J. Strasburger, A. Bergmann High-sensitivity chemiluminescence immunoassays for detection of growth hormone doping in sports. Clin. Chem. 2009, 55, 445.
6. J. Bosch, M. Ueki, G. Such-Sanmartín, J. Segura, R. Gutiérrez-Gallego Tracking growth hormone abuse in sport: A comparison of distinct isoform-based assays. Anal. Chim. Acta 2012, 733, 56.
7. WADA Guidelines for application of hGH Isoform differential immunoassay. Version 1.0, June 2010. Available at: www.wada-ama.org/Documents/Resources/Guidelines/WADA_Guidelines_hGH%20Differential%20Immunoassays_EN_June10.pdf [14 May 2013].
8. M. Thevis, A. Thomas, W. Schänzer Herausforderung Dopingbekämpfung Gefährliche Substanzen, deren Missbrauch und Nachweis. Gyne 2012, 33, 24.
9. P. Roepstorff, J. Fohlman Proposal for a common nomencalture for sequence ions in mass-spectra of peptides. Biomed. Mass Spectrom. 1984, 11, 601.
10. A. Thomas, K. Walpurgis, O. Krug, W. Schänzer, M. Thevis Determination of prohibited, small peptides in urine for sports drug testing by means of nano-liquid chromatography/benchtop quadrupole orbitrap tandem-mass spectrometry. J. Chromatogr. A 2012, 1259, 251.
11. A. Thomas, S. Höppner, H. Geyer, W. Schänzer, M. Petrou, D. Kwiatkowska, A. Pokrywka, M. Thevis Determination of growth hormone releasing peptides (GHRP) and their major metabolites in human urine for doping controls by means of liquid chromatography mass spectrometry. Anal. Bioanal. Chem. 2011, 401, 507.